4 completed, 3 terminated. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 3 |
| Phase 2 | 5 | Terminated 3, Completed 2 |
Follow bemcentinib: new trials by email Literature Review of bemcentinib trials Research Report on bemcentinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma bemcentinib, pacritinib - Advanced Lung Adenocarcinoma | Phase 1 / Phase 2 | Terminated | The University of Texas Health Science Center at San Antonio | 4 | 2024-12-27 | 2026-05-26 |
| A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene Bemcentinib, Pembrolizumab, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | BerGenBio ASA | 26 | 2023-03-03 | 2025-10-29 |
| A Study to Investigate 14C-bemcentinib in Healthy Male Subjects Bemcentinib - Non-Small Cell Lung Cancer, Metastatic Melanoma | Phase 1 | Completed | BerGenBio ASA | 6 | 2022-08-02 | 2025-01-29 |
| Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer Bemcentinib, Nab-paclitaxel, Gemcitabine - Cancer of Pancreas | Phase 1 / Phase 2 | Terminated | University of Texas Southwestern Medical Center | 9 | 2019-01-03 | 2023-11-09 |
| Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. BGB324, Docetaxel - Non-Small Cell Lung Carcinoma | Phase 1 | Completed | University of Texas Southwestern Medical Center | 23 | 2016-11-01 | 2024-02-21 |
| A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Erlotinib, Bemcentinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | BerGenBio ASA | 40 | 2015-04-19 | 2025-02-26 |
| A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Bemcentinib, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | BerGenBio ASA | 122 | 2014-10-22 | 2024-12-19 |
Carcinoma, Non-Small-Cell Lung (4) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Pancreatic Neoplasms (2) · COVID-19 (1) · Glioblastoma (1) · Melanoma (1) · Mesothelioma, Malignant (1)
BerGenBio ASA (4) · University of Texas Southwestern Medical Center (2) · The University of Texas Health Science Center at San Antonio (1)
United States (6) · Italy (2) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Norway (1) · Poland (1) · Spain (1) · United Kingdom (1)
David E Gerber, MD (1) · Dr. Lauren Byers, MD (1) · Sonja Loges, MD (1) · Syed Kazmi, MD (1)
R01CA269766 (1)